Search

Your search keyword '"Maria Carla Tablante"' showing total 2 results
Start Over Author "Maria Carla Tablante" Topic capsule endoscopy
2 results on '"Maria Carla Tablante"'

1. Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab

Author

Shinji Okabayashi, Taku Kobayashi, Tomohisa Sujino, Ryo Ozaki, Satoko Umeda, Takahiko Toyonaga, Eiko Saito, Masaru Nakano, Maria Carla Tablante, Shojiroh Morinaga, and Toshifumi Hibi

Subjects
Ulcerative colitis, Enteritis, Inflammatory bowel disease, Capsule endoscopy, Balloon-assisted enteroscopy, Medicine, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Extracolonic involvement of the gastrointestinal tract is extremely uncommon in ulcerative colitis (UC) and rarely found in the upper gastrointestinal tract or in postoperative cases since it typically responds to steroids. Here we report a case of UC complicated by extensive ileal inflammation that was refractory to steroids. A 20-year-old man was diagnosed with UC of typical pancolitis without ileal involvement and started treatment with pH-dependent mesalazine and oral prednisolone. Although his symptoms transiently resolved, the condition flared when the steroid dose was tapered down. Computed tomography revealed marked thickening of the ileal wall, and capsule endoscopy and balloon-assisted enteroscopy found diffuse mucosal inflammation with ulcers in the ileum. On the contrary, the inflammation in the colon and rectum was improving. Since the response to the second steroid course was inadequate, treatment with adalimumab and 6-mercaptopurine was initiated and finally achieved clinical and endoscopic remission. The investigation of small intestinal lesions is necessary in patients with UC whose clinical deterioration cannot be explained by colonic lesions.

Published
2017
Full Text
View/download PDF

2. A Simple 1-Day Colon Capsule Endoscopy Procedure Demonstrated to be a Highly Acceptable Monitoring Tool for Ulcerative Colitis

Author

Shinji Okabayashi, Toshifumi Hibi, Maria Carla Tablante, Masaru Nakano, Satoshi Kuronuma, Ryo Ozaki, Osamu Takeuchi, Takahiko Toyonaga, and Taku Kobayashi

Subjects
Adult, Male, medicine.medical_specialty, Colonoscopy, Capsule Endoscopy, Severity of Illness Index, Gastroenterology, law.invention, Excretion, Feces, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Capsule endoscopy, law, Internal medicine, medicine, Humans, Immunology and Allergy, Prospective Studies, Colitis, Prospective cohort study, Aged, Monitoring, Physiologic, Aged, 80 and over, medicine.diagnostic_test, business.industry, Middle Aged, Prognosis, medicine.disease, Ulcerative colitis, Regimen, 030220 oncology & carcinogenesis, Colitis, Ulcerative, Female, 030211 gastroenterology & hepatology, Calprotectin, business, Leukocyte L1 Antigen Complex, Follow-Up Studies
Abstract

Background Second-generation colon capsule endoscopy (CCE-2) has been reported as a potential tool for monitoring ulcerative colitis (UC). However, its excretion rate is still unsatisfactory, and the bowel preparation regimen is not well tolerated. Furthermore, a standard bowel preparation regimen validated for UC has not been established. The aim of this study was to develop a simple 1-day CCE-2 procedure while evaluating its excretion rate and acceptability in UC. Factors associated with the colonic transit time and acceptability of CCE-2 were evaluated. Methods Thirty-three patients were prospectively evaluated. Five hundred milliliters of hypertonic polyethylene glycol solution, followed by 250 mL of water, was ingested 2.5 hours before, then 1, 3, and 6 hours after capsule ingestion until its excretion, with castor oil added to the second ingestion. Mayo endoscopic subscore (MES) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) were graded, and their correlations with fecal calprotectin (FC) were assessed. A questionnaire comparing CCE-2 with previous colonoscopy (CS) was conducted. Results The excretion rate was 93.9% (31/33). The acceptability of CCE-2 was superior to CS (CCE-2 42.4% vs CS 27.3%). The median colonic transit time was 119 minutes and showed a positive correlation with MES (P = 0.010), UCEIS (P = 0.010), and FC (P = 0.041). CCE-2 was not favored by patients whose colonic transit times were longer. Conclusions A novel bowel preparation regimen of CCE-2 was well tolerated, with a high excretion rate, by UC patients. Patients with active disease required longer colonic transit time, which may have resulted in the lower acceptability of CCE-2.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results